Streetbeat News

TWST

Twist Bioscience Corporation

https://www.twistbioscience.com

Industry

Medical - Diagnostics & Research

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Open

46.88

Mkt cap

2.9B

Volume

927K

High

49.75

P/E Ratio

-13.45

52-wk high

60.90

Low

46.64

Div yield

N/A

52-wk low

27.41

Twist Bioscience (TWST) has formed a hammer chart pattern, suggesting potential support and a possible trend reversal. Additionally, upward revisions in earnings estimates could further bolster the stock's performance in the near term.

Portfolio Pulse from

December 16, 2024 | 4:15 pm

Twist Bioscience is showing strong growth in its SynBio and NGS segments, with improving margins and a path to cash flow breakeven. However, the biopharma segment's prospects are uncertain due to the sale of milestones and royalties to XOMA.

Portfolio Pulse from

November 29, 2024 | 3:15 pm

Twist Bioscience reported strong Q4 sales growth, leading to a rise in its stock price. Despite this, the company remains unprofitable with projected losses for several years, though it has a solid balance sheet and significant net loss carry forwards.

Portfolio Pulse from

November 18, 2024 | 8:30 pm

Twist Bioscience Corporation (TWST) held its Q4 2024 earnings call, discussing financial results and company updates. Key participants included executives and analysts from major financial institutions.

Portfolio Pulse from

November 18, 2024 | 4:45 pm

Twist Bioscience (TWST) reported a Q4 loss of $0.59 per share, which was better than the Zacks Consensus Estimate of a $0.73 loss. This is an improvement from the $0.81 loss per share reported a year ago.

Portfolio Pulse from

November 18, 2024 | 2:45 pm

Twist Bioscience Corporation (NASDAQ: TWST) announced its financial results for the fourth quarter and full year fiscal 2024, highlighting its performance in the life sciences segment.

Portfolio Pulse from

November 18, 2024 | 12:30 pm

Twist Bioscience has made significant progress with new partnerships, innovative products, and strategic financial agreements. Its valuation is now more reasonable, making it a compelling buy. The company has improved its gross margins and reduced EBIT margins, indicating rapid margin improvement.

Portfolio Pulse from

November 08, 2024 | 10:30 am

Ark Innovation ETF (ARKK) and Ark Genomic Revolution ETF (ARKG), both managed by Cathie Wood's Ark Funds, celebrate their 10th anniversaries. Despite strong growth in the past, both ETFs have underperformed the S&P 500 in recent years. ARKK focuses on disruptive innovation, while ARKG targets the genomics revolution. The funds' active management style and focus on long-term growth mean returns can take years to materialize.

Portfolio Pulse from Chris Katje

October 31, 2024 | 7:23 pm

Absci Corporation and Twist Bioscience Corporation have announced a collaboration to design a novel therapeutic using generative AI. This partnership combines Absci's expertise in AI-driven drug creation with Twist's synthetic DNA technology.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:28 pm

Twist Bioscience has entered into a royalty purchase agreement with XOMA Corporation. XOMA will provide Twist with a $15 million upfront payment in exchange for the right to receive half of future potential milestones earned under Twist's antibody discovery and biopharma services collaborations.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 12:13 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.